.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Cerilliant
Merck
Daiichi Sankyo
Novartis
Queensland Health
Cipla
Farmers Insurance
Boehringer Ingelheim

Generated: September 21, 2017

DrugPatentWatch Database Preview

SUSTOL Drug Profile

« Back to Dashboard

Which patents cover Sustol, and what generic Sustol alternatives are available?

Sustol is a drug marketed by Heron Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has sixteen patent family members in ten countries.

The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the granisetron profile page.

Summary for Tradename: SUSTOL

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list21
Patent Applications: see list4,828
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SUSTOL at DailyMed

Pharmacology for Tradename: SUSTOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SUSTOL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,861,068 Pharmaceutical compositions using semi-solid delivery vehicle► Subscribe
8,252,306Process for preparing a semi-solid delivery vehicle comprising granisetron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SUSTOL

Country Document Number Estimated Expiration
South Korea20070083851► Subscribe
Spain2529574► Subscribe
China101052376► Subscribe
Japan2012107064► Subscribe
Australia2005289425► Subscribe
Japan2017008113► Subscribe
Japan2008514646► Subscribe
European Patent Office2902012► Subscribe
Canada2579297► Subscribe
European Patent Office1796629► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Novartis
Express Scripts
Queensland Health
US Department of Justice
Colorcon
Medtronic
Farmers Insurance
US Army
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot